A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs BIIB 076 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Biogen
- 05 Mar 2018 Planned End Date changed from 19 Apr 2019 to 14 May 2019.
- 05 Mar 2018 Planned primary completion date changed from 19 Apr 2019 to 14 May 2019.
- 05 Mar 2018 Status changed from recruiting to active, no longer recruiting.